论文部分内容阅读
目的分析马来酸依那普利叶酸片对H型高血压脑卒中的预防作用。方法选取医院2013年8月-2016年8月收治的H型高血压患者600例,随机分为观察组和对照组各300例。对照组口服马来酸依那普利片,观察组口服马来酸依那普利叶酸片。随访3年,比较2组患者治疗前与治疗后1年、2年、3年血压、血清同型半胱氨酸(Hcy)及脑卒中发生率。结果 2组血压治疗前无显著差异(P>0.05),治疗后2组血压均有所减低,与治疗前比较差异有统计学意义(P<0.05),但2组血压比较无显著差异(P>0.05)。2组Hcy水平治疗前无显著差异(P>0.05),治疗后2组Hcy水平均有所改善,与治疗前比较差异有统计学意义(P<0.05),但观察组改善情况优于对照组,2组比较差异有统计学意义(P<0.05)。观察组脑卒中发生率为2.33%低于对照组的9.33%,差异有统计学意义(P<0.05)。结论马来酸依那普利叶酸片可更有效地减少H型高血压脑卒中的发生,值得临床推广使用。
Objective To analyze the preventive effect of enalapril maleate folate tablets on Hypertensive stroke. Methods Six hundred and sixty H-type hypertensive patients admitted from August 2013 to August 2016 in our hospital were randomly divided into observation group (n = 300) and control group (n = 300). The control group was given enalapril maleate orally, and the observation group was given oral enalapril folate tablets. The patients were followed up for 3 years. The blood pressure, serum homocysteine (Hcy) and the incidence of stroke were compared between two groups before treatment and one year after treatment, two years and three years after treatment. Results There was no significant difference in blood pressure between the two groups before treatment (P> 0.05). The blood pressure of the two groups decreased after treatment, with significant difference from before treatment (P <0.05), but there was no significant difference between the two groups > 0.05). There was no significant difference in Hcy levels between the two groups before treatment (P> 0.05). Hcy levels in both groups were improved after treatment, with statistical significance (P <0.05), but the improvement in observation group was better than that in control group , The difference between the two groups was statistically significant (P <0.05). The incidence of stroke in the observation group was 2.33% lower than that in the control group (9.33%), the difference was statistically significant (P <0.05). Conclusion Enalapril maleate folate tablets can reduce the incidence of H-type hypertension stroke more effectively and is worthy of clinical promotion.